Genelux Corporation Common Stock (GNLX)

FairStock Score: 19/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

Genelux is a clinical-stage biopharmaceutical company with 25 employees. Its lead asset, Olvi-Vec, targets ovarian cancer and other solid tumors. The financial record is stark. In fiscal 2023, the year ended 2023-12-31, revenue was $170,000 and net loss was $28.3M, with diluted EPS of -$1.16. In fiscal 2024, the year ended 2024-12-31, revenue was $8,000 and net loss was $29.9M, with diluted EPS of -$0.95. In fiscal 2025, the year ended 2025-12-31, revenue was $8,000 and net loss was $32.1M, with diluted EPS of -$0.86. In fiscal Q2 2026, the quarter ended 2026-06-30, net loss was $9.5M and diluted EPS was -$0.21. FairStock's trailing free cash flow is -$28.7M, a -25.2% FCF yield on the $114.0M market cap. Its ratios show ROE of -177.93%, ROCE of -77.89%, Piotroski F-Score of 1/9, and Altman Z-Score of -10.03. Debt is low with D/E of 0.15, but that does not offset the cash burn. At the close on 2026-10-13, the price was $2.52, with FairStock P/E -2.93 and P/B 7.00; its score is 19/100, and the Lynch category is none because of losses in each of the last four years. A moat here would have to come from clinical data and intellectual property, not from earnings power. Graham would want asset protection and earnings stability; I see neither. Buffett would want durable owner earnings; I see a speculative option on a pipeline.

In plain English: Genelux is a small drug developer working on virus-based cancer treatments, led by a product for ovarian cancer. It has almost no sales and loses tens of millions of dollars a year, burns cash, and looks financially fragile. At $2.52, the price is not supported by profits or sales, so it looks expensive as a business and depends on future trial success.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer